The phase II and phase III trials, namely HERTHENA-Lung01 (NCT04619004) and HERTHENA-Lung02 (NCT05338970), are actively recruiting to further confirm the efficacy and safety of patritumab deruxtecan in patients with EGFR-mutant NSCLC with disease progression on EGFR TKI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.